Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures
Conditions
Interventions
GWP42003-P
Placebo
Locations
44
United States
UAB Epilepsy Center
Birmingham, Alabama, United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
UCLA-Pediatric Neurology
Los Angeles, California, United States
UCSF Benioff Children's Hospital Oakland
Oakland, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Pediatric Neurology
Miami, Florida, United States
Start Date
April 6, 2016
Primary Completion Date
January 22, 2019
Completion Date
February 26, 2019
Last Updated
September 28, 2022
NCT05077904
NCT05667142
NCT07234695
NCT03492060
NCT07141329
NCT05594017
Lead Sponsor
Jazz Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions